{"id":432631,"date":"2021-02-10T07:03:18","date_gmt":"2021-02-10T12:03:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=432631"},"modified":"2021-02-10T07:03:18","modified_gmt":"2021-02-10T12:03:18","slug":"tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/","title":{"rendered":"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CHATHAM, N.J., Feb.  10, 2021  (GLOBE NEWSWIRE) &#8212; Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the BIO CEO &amp; Investor Digital Conference being held February 16-18, 2021.<\/p>\n<p align=\"justify\">The Company\u2019s presentation will be made through the BIO CEO &amp; Investor Digital Conference website and available on demand to registered participants during the conference at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L-6BVGq6QyCuxt02BSvlenQHzI4prHwJ4NVw091oAEh4WpUQbgbx0ODWyYnuY-DftrdoXECnp-4Jjry0z93TqRpGL1bPu4frYSTSZvKu8dzNOaRdILgsbu9IPkuT8u9k1c-F_FXiAt1OKkxRZy8UHPPn2a5Jx6WEP4-2vfWmgSNzTplNObmrIFBAz4Jlmph-oZlACUmKc9s8xH5-yBNgfOMeZQejNxRLP6sg50JZGMShJhcydBPeyflSiQhKTE2-\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.bio.org\/events\/bio-ceo-investor-digital-conference\/company-presentations<\/a>. Following the conference, the presentation will be available under the IR Events tab of the Investors section of the Tonix website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VQtZm1CcbvNPJyvHXgfxFvFa2aW4MlZcZgQdxCyjS3S73zv0vgeKWr_JkIeKgRobAlAvn1-43i9Eyn29AfGZkGelkUKyLHxy_3CQbeQKRJ4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.tonixpharma.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong> About Tonix Pharmaceuticals Holding Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix\u2019s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix\u2019s lead CNS candidate, TNX-102 SL<sup>1<\/sup>, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the second quarter of 2021<sup>2<\/sup> and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix\u2019s lead vaccine candidate, TNX-1800<sup>3<\/sup>, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801<sup>3<\/sup>, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.<\/p>\n<p align=\"justify\">\n        <sup>1<\/sup>TNX-102 SL is an investigational new drug and has not been approved for any indication.<\/p>\n<p align=\"justify\">\n        <sup>2<\/sup>Pending submission and agreement from FDA on statistical analysis plan.<\/p>\n<p align=\"justify\">\n        <sup>3<\/sup>TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.<\/p>\n<p align=\"justify\">This press release and further information about Tonix can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VQtZm1CcbvNPJyvHXgfxFinKcViHrjOcbprbU3rgojp_RvKla2f5Y71zK3zig5qzZi8CbyjGYJT33ECIWK-dBI0Q7dKzgMF2l_WJjl3AztQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.tonixpharma.com<\/a>.<\/p>\n<p align=\"justify\">Jessica Morris (corporate)<br \/>Tonix Pharmaceuticals<br \/>investor.relations@tonixpharma.com<br \/>(862) 904-8182<\/p>\n<p align=\"justify\">Olipriya Das, Ph.D. (media)<br \/>Russo Partners<br \/>Olipriya.Das@russopartnersllc.com <br \/>(646) 942-5588<\/p>\n<p align=\"justify\">Peter Vozzo (investors)<br \/>Westwicke, an ICR Company<br \/>peter.vozzo@westwicke.com <br \/>(443) 213-0505<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b944f4cb-fa18-45ab-9d52-3d0ba8f126c6\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CHATHAM, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) &#8212; Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the BIO CEO &amp; Investor Digital Conference being held February 16-18, 2021. The Company\u2019s presentation will be made through the BIO CEO &amp; Investor Digital Conference website and available on demand to registered participants during the conference at https:\/\/www.bio.org\/events\/bio-ceo-investor-digital-conference\/company-presentations. Following the conference, the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com. About Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-432631","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CHATHAM, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) &#8212; Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the BIO CEO &amp; Investor Digital Conference being held February 16-18, 2021. The Company\u2019s presentation will be made through the BIO CEO &amp; Investor Digital Conference website and available on demand to registered participants during the conference at https:\/\/www.bio.org\/events\/bio-ceo-investor-digital-conference\/company-presentations. Following the conference, the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com. About Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules &hellip; Continue reading &quot;Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-10T12:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference\",\"datePublished\":\"2021-02-10T12:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/\"},\"wordCount\":397,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/\",\"name\":\"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI=\",\"datePublished\":\"2021-02-10T12:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/","og_locale":"en_US","og_type":"article","og_title":"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference - Market Newsdesk","og_description":"CHATHAM, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) &#8212; Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the BIO CEO &amp; Investor Digital Conference being held February 16-18, 2021. The Company\u2019s presentation will be made through the BIO CEO &amp; Investor Digital Conference website and available on demand to registered participants during the conference at https:\/\/www.bio.org\/events\/bio-ceo-investor-digital-conference\/company-presentations. Following the conference, the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com. About Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules &hellip; Continue reading \"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-10T12:03:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference","datePublished":"2021-02-10T12:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/"},"wordCount":397,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/","name":"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI=","datePublished":"2021-02-10T12:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1MDI5NyMzOTY4ODcxIzIwMTExMTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tonix Pharmaceuticals to Participate in BIO CEO &amp; Investor Digital Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/432631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=432631"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/432631\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=432631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=432631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=432631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}